BioCentury
ARTICLE | Strategy

Qrating assets

How Mayo and nference’s JV Qrativ plans to use AI to source and develop compounds

September 14, 2017 11:34 PM UTC

Launched in July, Qrativ Holdings LLC is the latest venture to apply artificial intelligence to drug development, carving out a new niche by using AI to find uses for discarded early stage compounds, rather than marketed ones, and home in on an optimal path to market.

Qrativ is a JV between Mayo Clinic and AI company nference Inc., designed to combine the former’s clinical data and expertise with the latter’s intelligence platform. The company was launched with an $8.3 million series A round from Mayo, nference, Matrix Capital Management and Matrix Partners. ...